Zobrazeno 1 - 10 of 52 pro vyhledávání: '"I. van Moort"'
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Desmopressin testing in von Willebrand disease: Lowering the burden
Autor: Jessica M. Heijdra, Ferdows Atiq, Wala Al Arashi, Quincy Kieboom, Esmee Wuijster, Karina Meijer, Marieke J.H.A. Kruip, Frank W.G. Leebeek, Marjon H. Cnossen, K. Fijnvandraat, R.A.A. Mathôt, S. Polinder, M. Coppens, R.Y.J. Tamminga, K. Meijer, B.A.P. Laros‐van Gorkom, P. Brons, S.E.M. Schols, F.J.M. van der Meer, H.C.J. Eikenboom, R.E.G. Schutgens, K. Fischer, F. Heubel‐Moenen, L. Nieuwenhuizen, P. Ypma, M.H.E. Driessens, C.M. Zwaan, I. van Vliet, P.W. Collins, R. Liesner, P. Chowdary, D. Keeling, J. Lock, H.C.A.M. Hazendonk, I. van Moort, T. Preijers, N.C.B. de Jager, M.C.H.J. Goedhart, L.H. Bukkems, M.E. Cloesmeijer, A. Janssen
Publikováno v: Research and practice in thrombosis and haemostasis, 6(6):e12784. Wiley-Blackwell Publishing Ltd
Research and Practice in Thrombosis and Haemostasis, 6(6):e12784. Wiley-Blackwell Publishing Ltd
Research and practice in thrombosis and haemostasis, 6(6):e12784. Wiley
Background: Individuals with von Willebrand disease (VWD) require desmopressin testing because of interindividual response differences. However, testing is burdensome, while not all patients may need extensive testing.Objectives: To provide von Wille
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e0a565361a6f821a227ac15b88756ac
https://pure.amc.nl/en/publications/desmopressin-testing-in-von-willebrand-disease(e39b8cf5-28d9-4e8d-aaea-05ff14efa6d6).html
Zobrazit plný text záznamu
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
5
Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT:to WiN study
Autor: Marjon H Cnossen, Frank W G Leebeek, Ron A A Mathôt, M Coppens, MJHA Kruip, S Polinder, K Fischer, R Liesner, K Fijnvandraat, Laura H Bukkems, PW Collins, P Chowdary, K Meijer, A Janssen, MH Cnossen, Jessica M Heijdra, Wala Al Arashi, Nico C B de Jager, Michael E Cloesmeijer, Christian M Zwaan, FWG Leebeek, RAA Mathôt, RYJ Tamminga, BAP Laros-van Gorkom, P Brons, SEM Schols, FJM van der Meer, HCJ Eikenboom, REG Schutgens, F Heubel-Moenen, L Nieuwenhuizen, P Ypma, MHE Driessens, CM Zwaan, I van Vliet, D Keeling, J Lock, HCAM Hazendonk, I van Moort, T Preijers, JM Heijdra, NCB de Jager, MCHJ Goedhart, LH Bukkems, W Al Arashi, ME Cloesmeijer
Publikováno v: BMJ Open, Vol 12, Iss 2 (2022)
BMJ open, 12(2):e049493. BMJ Publishing Group
BMJ Open, 12(2):e049493. BMJ Publishing Group
IntroductionVon Willebrand disease (VWD) is a bleeding disorder, caused by a deficiency or defect of von Willebrand factor (VWF). In case of medical procedures or bleeding, patients are treated with desmopressin and/or VWF-containing concentrates to
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3000ab9c941592fab1ee1b9d3a0398a5
https://doi.org/10.1136/bmjopen-2021-049493
Zobrazit plný text záznamu
6
Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII
Autor: R. A. A. Mathôt, I. van Moort, Karin Fijnvandraat, Frank W.G. Leebeek, Tim Preijers, Marjon H. Cnossen
Publikováno v: Thrombosis and Haemostasis, 118(3), 514-525. Georg Thieme Verlag
Thrombosis and haemostasis, 118(3), 514-525. Schattauer GmbH
Background Patients with severe and moderate haemophilia A are treated prophylactically with factor VIII (FVIII) concentrate. Individualization of prophylaxis can be achieved by pharmacokinetic (PK)-guided dosing. Aim In this study, the performance o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34c9049f4f23ce4857c248e29f1a34a5
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85044164294&origin=inward
Zobrazit plný text záznamu
7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
8
Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery
Autor: T. Preijers, H.C.A.M. Hazendonk, R. Liesner, P. Chowdary, M.H.E. Driessens, D. Hart, D. Keeling, B.A.P. Laros‐van Gorkom, F.J.M. van der Meer, K. Meijer, K. Fijnvandraat, F.W.G. Leebeek, P.W. Collins, M.H. Cnossen, R.A.A. Mathôt, M.J.A.H. Kruip, S. Polinder, J. Lock, I. van Moort, J.M. Heijdra, A. Nederlof, N. de Jager, M. Coppens, M. Peters, R.Y.J. Tamminga, P. Brons, H.C.J. Eikenboom, R.E.G. Schutgens, K. Fischer, C.M. Zwaan, I. van Vliet
Publikováno v: Journal of Thrombosis and Haemostasis, 16, 2196-2207
Journal of Thrombosis and Haemostasis, 16(11), 2196. Wiley-Blackwell
Journal of Thrombosis and Haemostasis, 16(11), 2196-2207. Wiley-Blackwell Publishing Ltd
Journal of Thrombosis and Haemostasis, 16(11), 2196-2207. Wiley
Journal of Thrombosis and Haemostasis, 16, 11, pp. 2196-2207
Journal of Thrombosis and Haemostasis, 16(11), 2196-2207
Journal of thrombosis and haemostasis, 16(11), 2196-2207. Wiley-Blackwell
Journal of Thrombosis and Haemostasis
Essentials Factor IX (FIX) dosing using body weight frequently results in under and overdosing during surgery. We aimed to establish a population pharmacokinetic (PK) model describing the perioperative FIX levels. Population PK parameter values for c
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61f94ed84d6470544934de10d2aaabc5
https://dspace.library.uu.nl/handle/1874/374586
Zobrazit plný text záznamu
9
Analysis of current perioperative management with Haemate
Autor: H C A M, Hazendonk, J M, Heijdra, N C B, de Jager, H C, Veerman, J, Boender, I, van Moort, R A A, Mathôt, K, Meijer, B A P, Laros-van Gorkom, J, Eikenboom, K, Fijnvandraat, F W G, Leebeek, M H, Cnossen
Publikováno v: Haemophilia : the official journal of the World Federation of Hemophilia. 24(3)
Patients with Von Willebrand disease (VWD) are regularly treated with VWF-containing concentrates in case of acute bleeding, trauma and dental or surgical procedures.In this multicentre retrospective study, current perioperative management with a von
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d8d137c52bd466dd6e0fa94f4294add8
https://pubmed.ncbi.nlm.nih.gov/29665194
Zobrazit plný text záznamu
10
Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?
Autor: Marjon H. Cnossen, Peter William Collins, Ron A. A. Mathôt, Karin Fijnvandraat, Frank W.G. Leebeek, Hendrika C A M Hazendonk, I. van Moort
Publikováno v: Blood Reviews, 32(4), 265-271. Churchill Livingstone
Blood reviews, 32(4), 265-271. Churchill Livingstone
Replacement therapy with clotting factor concentrates (CFC) is the mainstay of treatment in hemophilia. Its widespread application has led to a dramatic decrease in morbidity and mortality in patients, with concomitant improvement of quality of life.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e97bfbbcea9a824a1f93d1e0f41577ef
https://pubmed.ncbi.nlm.nih.gov/29426727
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje